Modern Interoperability: How APIs Can Heal a Fragmented System

The go-to mechanisms for differential payment – network design, case management, quality measurement and prior authorization – increasingly rely on APIs capable of handling not only claims data but, more importantly, the clinical data critical to intelligent decision-making. The post Modern Interoperability: How APIs Can Heal a Fragmented System appeared first on MedCity News.

Read More

Poll: 1 in 3 ACA Marketplace Enrollees Say They Would “Very Likely” Shop for a Cheaper Plan If Their Premium Payments Doubled; 1 in 4 Say They “Very Likely” Would Go Without Insurance

If the amount they pay in premiums doubled, about one in three enrollees in Affordable Care Act Marketplace health plans say they would be “very likely” to look for a lower-premium Marketplace plan (with higher deductibles and co-pays) and one in four would “very likely” go without insurance next year, finds a new survey of…

Read More

2025 KFF Marketplace Enrollees Survey

This survey explores how ACA Marketplace enrollees expect to respond if their premium payments doubled as expected in 2026 when enhanced premium tax credits are set to expire. About a third would very likely look for a lower-cost plan, even if it had higher deductibles, and about a quarter would very likely end up uninsured….

Read More

What Is Philips Showing Off at RSNA This Year?

Philips showcased two major imaging innovations at RSNA 2025 — one a CT system that integrates AI into its hardware, and the other a new helium-free MRI model that embeds AI directly into signal acquisition. Both aim to improve image quality, efficiency and ease of integration — but commercial availability and real-world adoption are still…

Read More

Pharvaris Drug for Rare Swelling Disease Meets Phase 3 Goals; FDA Filing Planned for 2026

Pharvaris’s deucrictibant met the main and secondary goals of its Phase 3 test as an on-demand treatment for swelling attacks caused by the rare disease hereditary angioedema. Pharvaris’s capsule could compete against Kalvista Pharmaceuticals’ Ekterly, an HAE pill approved by the FDA over the summer. The post Pharvaris Drug for Rare Swelling Disease Meets Phase…

Read More